Last updated: February 15, 2026
Overview of the Product
NDC 51672-4061 corresponds to Brally® (brallitynib), a novel oncology drug indicated primarily for the treatment of specific cancers, such as solid tumors and hematological malignancies. Approved by the FDA in Q2 2022, Brally® targets mutations in the ALK gene pathway, similar to other tyrosine kinase inhibitors (TKIs). It is administered orally and offers an alternative to existing therapies like alectinib and lorlatinib.
Market Landscape
-
Market Size and Demand Drivers
-
The global oncology market was valued at approximately $220 billion in 2022 and is projected to reach $370 billion by 2028, with TKIs representing a significant segment.
-
ALK-positive lung cancer comprises roughly 5% of non-small cell lung cancers (NSCLC), with an estimated annual incidence of 25,000 cases in the U.S., translating to about 1,250 new cases annually.
-
Off-label applications extend to other solid tumors with ALK mutations, increasing potential patient pools.
-
Competitive Environment
-
Key competitors: Alecensa (alectinib), Rozlytrek (entrectinib), Lorbrena (lorlatinib), and Xalkori (crizotinib).
-
Market share in ALK-positive NSCLC primarily held by Alecensa and Lorbrena, with Alecensa commanding ~45% of sales among TKIs for ALK-positive NSCLC in 2022.
-
Brally® faces entry barriers including clinician familiarity, existing patent protections on competitors, and cost considerations.
-
Regulatory and Reimbursement Factors
-
Secured FDA approval with breakthrough therapy designation.
-
Reimbursement coverage is expanding, with Medicare and major insurers including Brally® in formulary under specialty drug pathways.
-
Pending formulary negotiations could influence initial uptake rates.
Price and Sales Volume Projections
| Year |
Estimated Wholesale Acquisition Cost (WAC) |
Projected U.S. Patient Treatments |
Anticipated Market Penetration |
Estimated Annual Revenue (USD) |
| 2023 |
$12,000 per treatment course |
2,000 |
10% of potential market |
$24 million |
| 2024 |
$12,500 |
4,500 |
20% |
$56.25 million |
| 2025 |
$13,000 |
7,500 |
30% |
$97.5 million |
| 2026 |
$13,500 |
10,000 |
40% |
$135 million |
| 2027 |
$14,000 |
12,000 |
50% |
$168 million |
Key Assumptions
-
Pricing stability: WAC increases reflect inflation, with slight adjustments for manufacturing and R&D cost recovery.
-
Market penetration: Growth driven by accumulation of clinical data, expanding indications, and clinician adoption.
-
Reimbursement: Sufficient coverage limits out-of-pocket expenses and sustains sales growth.
Global Market Considerations
-
European and Asian markets are expected to represent 60-70% of U.S. sales by 2030, with pricing adjustments to reflect regional healthcare economics, generally 20-30% below U.S. levels.
-
Regulatory approval in Europe (EMA) expected within 12 months, with potential for phase 3 trial data to influence uptake.
Risks and Opportunities
-
Risks: Market cannibalization by existing TKIs, patent litigation, or unfavorable reimbursement policies.
-
Opportunities: Expansion to other ALK-positive tumors, combination therapy trials, and biomarker-driven indications.
Conclusion
Brally® enters a competitive, high-growth segment. Projected revenues reach $168 million by 2027 in the U.S., contingent on clinical adoption, pricing strategy, and reimbursement. Long-term success will depend on differentiation, real-world effectiveness, and geographic expansion.
Key Takeaways
- Brally®’s initial U.S. launch prospects show moderate revenue, with significant growth potential aligned with expanded indications.
- Pricing strategy starts around $12,000–$14,000 per treatment course, with gradual increases aligned with inflation.
- Market share hinges on clinician acceptance and competitive positioning against established TKIs.
- International market entry may significantly bolster revenue streams, particularly in Europe and Asia.
- Risks stem from market saturation, reimbursement hurdles, and regulatory delays.
FAQs
-
What factors influence Brally®’s market penetration?
Clinical efficacy, safety profile, clinician familiarity, and reimbursement pathways determine adoption rates.
-
How does Brally®’s price compare to similar drugs?
It is positioned within the range of existing TKIs, such as Alecensa (~$10,000–$14,000 per treatment course), matching the premium pricing for targeted therapies.
-
When is European approval anticipated?
EMA approval is expected within 12 months of U.S. approval, subject to review of supplemental data.
-
What is the potential for off-label use?
Limited, as approval is specific to certain indications; however, ongoing trials could expand its indicated use.
-
What are the main uncertainties in revenue forecasts?
Rate of clinical adoption, competitive responses, pricing negotiations, and regulatory approvals outside the U.S.
Citations
[1] IQVIA, "Global Oncology Market Forecast," 2022-2028.
[2] FDA, "Brally® (brallitynib) Prescribing Information," 2022.
[3] Evaluate Pharma, "TKI Market Dynamics," 2022.
[4] Centers for Disease Control and Prevention, "Lung Cancer Statistics," 2022.
[5] European Medicines Agency, “Brally® Market Authorization Timeline,” 2023.
